You may be eligible to file a ranitidine lawsuit if you’ve been prescribed this medication. This medicine has been linked to cancer and other adverse health effects and is currently the subject of multidistrict litigation (MDL) in the Southern District of Florida and the Eastern District of New York. Regardless of your age or health history, you may be eligible to file a ranitidine lawsuit if you were exposed to it as a child or as an adult.
If you’ve taken ranitidine and developed a rash or other adverse reaction, you may be entitled to compensation from the manufacturer.
Zantac lawsuits typically focus on the manufacturing defect of the drug. These cases often involve the duty to warn theory. While the process for filing a Zantac lawsuit is long and complicated, the key to success is the ability to prove the defendant’s negligence. By demonstrating that the defendants were negligent, plaintiffs can file a class action lawsuit and pursue a large financial settlement.
Consumers in New York and Virginia have recently filed a lawsuit against Perrigo for failing to warn them of the dangerous chemicals contained in their medications. The company’s negligence caused the high levels of NDMA in their product, and they were never warned about the risks. This has led to a class-action lawsuit that seeks compensation for the victims of these drugs. The plaintiffs seek to represent all purchasers of Ranitidine in New York and Virginia who suffered a similar outcome. The plaintiffs are also seeking full refunds of their purchase price, as well as statutory damages for exposure to these carcinogens.
The Virginia plaintiff has filed a class-action suit against drugmaker Sanofi and accused the company of concealing a link between the two drugs.
These lawsuits allege that Sanofi and Boehringer Ingelheim had to warn consumers of the potential dangers of the medications. The FDA issued its safety warning shortly after the first Zantac cancer lawsuit was filed. The lawsuit seeks to represent all consumers of Zantac in Virginia and New York who were exposed to NDMA-causing drugs. The plaintiffs are seeking to recover a full refund of the price they paid for the medication, statutory damages, and other damages that may be related to the defendants’ conduct.
A California plaintiff has filed a class-action lawsuit against generic ranitidine after being exposed to NDMA in the medication. This class action claims that the drug manufacturer knew or should have known that NDMA could cause cancer and other health problems. A Zantac plaintiff’s case seeks to represent all purchasers in Virginia and New York who were exposed to NDMA. They are seeking statutory damages, a full refund of their purchases, and damages related to her or his family’s loss.
While Zantac has faced thousands of lawsuits, most of them have focused on the potential for cancer to occur from NDMA.
These lawsuits are complex, however, and the chances of success are very low for a successful class action. Therefore, it is important to understand what ranitidine is and how it affects consumers. By learning about the potential risks associated with it, you will be able to decide if a lawsuit is right for you.
The plaintiff in the Virginia lawsuit purchased generic ranitidine from Walmart and later learned that NDMA had been found in her ranitidine. She was never warned about this and was unaware of the risk. Now she is seeking to represent all purchasers in New York and Virginia who were exposed to ranitidine, and he is suing the manufacturer of these medications. The plaintiff is seeking a full refund of his purchase price as well as statutory damages for the high level of NDMA that she was exposed to.
The Virginia plaintiff has filed a lawsuit alleging that she was exposed to NDMA from the generic ranitidine she purchased from Walmart.
She has since discovered that she had not been warned of the potential danger of this carcinogen, but was unaware of the risks of taking the medication. As a result, she is seeking compensation for all purchasers in New York and Virginia. The claims are based on the high levels of NDMA in ranitidine and the conduct of the manufacturer and retailer.